CD123 AML targeting by chimeric antigen

Receptors，A novel magic bullet for AML therapeutics?

CD123 AML通过靶向嵌合抗原受体，一种新的灵丹妙药AML疗法？

Abstract:

Chimeric antigen receptor (CAR) modified cells have emerged as powerful tools for controlling leukemias.  we recently showed that anti-CD123 CAR-expressing cytokine-induced killer t cell treatment is an effective immunotherapeutic approach to eradicate Acute Myeloid Leukemia (AML) cells. here, we discuss how this genetically modified cell-based strategy could be relevant to the field of AML therapeutics.

爱康得生物编译：

嵌合抗原受体（CAR）的改进型的T细胞已成为控制白血病强大的工具。我们最近发现，抗CD123 CAR表达的细胞因子诱导的杀伤T细胞治疗是消除急性髓系白血病（AML）细胞的有效免疫治疗的方法。

CD123 AML targeting by chimeric antigen receptor.pdf
文件大小：0.7M